Related Experiment Video
Updated: Sep 21, 2025
09:17
Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022
2.4K
Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas
Takaki Omura1, Masamichi Takahashi1, Makoto Ohno1
1Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan.
Cancers
|May 28, 2022
Summary
Comprehensive genomic profiling tests (CGPT) identified actionable therapies for 18.5% of glioma patients. This genomic analysis offers valuable diagnostic insights and potential treatment options for this challenging cancer.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Next-generation sequencing-based comprehensive genomic profiling tests (CGPT) identify molecularly targeted therapies.
- Glioma patients have limited standard treatment options and high recurrence rates.
- The clinical utility of CGPT in glioma patients remains underreported.
Purpose of the Study:
- To evaluate the comprehensive genomic profiling test (CGPT) results in glioma patients.
- To determine the clinical actionability of CGPT findings in this cohort.
- To identify common genomic aberrations in IDH-wildtype glioblastoma.
Main Methods:
- Retrospective analysis of 65 glioma patients who underwent CGPT.
- Assessment of genomic aberrations, tumor mutation burden, and microsatellite instability.
- Molecular Tumor Board (MTB) review for therapeutic recommendations and germline mutation assessment.
Main Results:
- 18.5% (12/65) of patients were eligible for at least one targeted therapy.
- 7.7% (5/65) of patients had suspected germline mutations.
- Frequent aberrations in IDH-wildtype glioblastoma included TERT promoter (67%), CDKN2A (57%), and CDKN2B (51%).
Conclusions:
- CGPT provides valuable clinical actionability for glioma patients.
- Genomic profiling can identify potential therapeutic targets and diagnostic insights.
- CGPT may improve treatment strategies for glioma patients with limited options.
